Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhibition of α-synuclein aggregation and mature fibril disassembling with a minimalistic compound, ZPDm

  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Navarro, Susanna|||0000-0001-8160-9536
  • Conde Giménez, María|||0000-0003-4358-9110
  • García, Jesús
  • Salvatella, Xavier|||0000-0002-8371-4185
  • Dalfo, Esther|||0000-0003-4677-8515
  • Sancho Sanz, Javier|||0000-0002-2879-9200
  • Ventura, Salvador|||0000-0002-9652-6351
Synucleinopathies are a group of disorders characterized by the accumulation of α-Synuclein amyloid inclusions in the brain. Preventing α-Synuclein aggregation is challenging because of the disordered nature of the protein and the stochastic nature of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic intervention in these pathologies. A high-throughput screening initiative allowed us to discover ZPDm, the smallest active molecule in a library of more than 14.000 compounds. Although the ZPDm structure is highly related to that of the previously described ZPD-2 aggregation inhibitor, we show here that their mechanisms of action are entirely different. ZPDm inhibits the aggregation of wild-type, A30P, and H50Q α-Synuclein variants in vitro and interferes with α-Synuclein seeded aggregation in protein misfolding cyclic amplification assays. However, ZPDm distinctive feature is its strong potency to dismantle preformed α-Synuclein amyloid fibrils. Studies in a Caenorhabditis elegans model of Parkinson's Disease, prove that these in vitro properties are translated into a significant reduction in the accumulation of α-Synuclein inclusions in ZPDm treated animals. Together with previous data, the present work illustrates how different chemical groups on top of a common molecular scaffold can result in divergent but complementary anti-amyloid activities.